Prime Medicine, Inc.
PRME
$3.55
$0.3310.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.96M | 3.85M | 2.98M | 800.00K | 591.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.96M | 3.85M | 2.98M | 800.00K | 591.00K |
| Cost of Revenue | 80.52M | 81.52M | 81.39M | 88.75M | 89.37M |
| Gross Profit | -75.56M | -77.68M | -78.41M | -87.95M | -88.78M |
| SG&A Expenses | 52.80M | 52.29M | 50.16M | 50.94M | 47.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 209.18M | 210.36M | 205.45M | 213.59M | 210.61M |
| Operating Income | -204.22M | -206.52M | -202.47M | -212.79M | -210.02M |
| Income Before Tax | -199.28M | -202.15M | -195.88M | -219.25M | -217.55M |
| Income Tax Expenses | -- | -134.00K | 0.00 | 0.00 | -108.00K |
| Earnings from Continuing Operations | -199.28 | -202.01 | -195.88 | -219.25 | -217.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -199.28M | -202.01M | -195.88M | -219.25M | -217.44M |
| EBIT | -204.22M | -206.52M | -202.47M | -212.79M | -210.02M |
| EBITDA | -197.38M | -200.01M | -196.34M | -207.13M | -204.68M |
| EPS Basic | -1.57 | -1.62 | -1.66 | -2.05 | -2.16 |
| Normalized Basic EPS | -0.98 | -1.02 | -1.06 | -1.22 | -1.28 |
| EPS Diluted | -1.57 | -1.62 | -1.66 | -2.05 | -2.16 |
| Normalized Diluted EPS | -0.98 | -1.02 | -1.06 | -1.22 | -1.28 |
| Average Basic Shares Outstanding | 510.76M | 500.76M | 474.34M | 435.89M | 407.97M |
| Average Diluted Shares Outstanding | 510.76M | 500.76M | 474.34M | 435.89M | 407.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |